干扰素介导的跨膜蛋白1与卵巢上皮性癌耐药相关性研究

Relationship between expression of IFITM1 and resistance of human ovarian carcinoma to cisplatin

目的:探讨干扰素介导的跨膜蛋白1(IFITM1)与卵巢上皮性癌化疗耐药性的相关性。方法:应用免疫组化测定68例初治卵巢上皮性癌组织和卵巢癌顺铂敏感细胞株A2780、顺铂耐药细胞株CP70中IFITM1的表达,Western blotting检测两种卵巢癌细胞株中IFITM1蛋白的表达。结果:免疫组织化学显示铂类化疗敏感性卵巢癌组和耐药性卵巢癌组的表达强度之间的差异有统计学意义(P=0.043),Western blot实验显示卵巢癌CP70细胞株中IFITM1表达水平明显高于A2780细胞株。结论:IFITM1表达强度与卵巢癌铂类化疗的敏感性相关,检测IFITM1对判断卵巢癌化疗疗效具有临床意义。

Objective：To investigate the relationship between expression of interferon - induced transmembrane protein 1 （ IFITM1 ） and the drug - resistance of platinum - based chemotherapy in human ovarian carcinoma. Methotis ：The immunohistoehemieal method （SP） was used to determine the expression levels of IFITM1 among 65 ovarian carcinoma cases, the human ovarian carcinoma A2780 cell line and the cisplatin - resistant cell line CP70. The expression level of IFITM1 was detected by Western blotting analysis in the cell lines A2780/CP70. Results ：The immunohistoehemical technique showed that the expression intensity of IFITM1 protein in ovarian carcinoma was signifi- cantly related to its chemotherapy sensitivity. Western blot analysis showed that IFITM1 expression in the CP70 cell lines was increased compared with A2780 cell lines. Conclusion：IFITM1 played a vital role in the drug - resistance to platinum - based chemotherapy of human ovarian carcinoma. Our research can provide better evidence to the effect of IFITM1 in treatment of ovarian carcinoma.